Maione et al., 2022 - Google Patents

Acromegaly

Maione et al., 2022

Document ID
2677339716374415141
Author
Maione L
Chanson P
Publication year
Publication venue
Pituitary Adenomas: The European Neuroendocrine Association’s Young Researcher Committee Overview

External Links

Snippet

Acromegaly is a rare disease (updated estimated prevalence: 80–130 cases per million inhabitants) that is due to excessive production and exposure to growth hormone (GH), generally driven by a pituitary GH-secreting adenoma. Acromegaly is characterized by …
Continue reading at link.springer.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
    • A61B6/48—Diagnostic techniques

Similar Documents

Publication Publication Date Title
Fleseriu et al. Acromegaly: pathogenesis, diagnosis, and management
Chanson et al. Acromegaly
Katznelson et al. Acromegaly: an endocrine society clinical practice guideline
Javaid et al. Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium
Bolanowski et al. Diagnostics and treatment of acromegaly—updated recommendations of the Polish Society of Endocrinology [Rozpoznanie i leczenie akromegalii—aktualizacja rekomendacji Polskiego Towarzystwa Endokrynologicznego]
Bolanowski et al. Acromegaly—a novel view of the patient. Polish proposals for diagnostic and therapeutic procedures in the light of recent reports
Ogedegbe et al. A comprehensive review of four clinical practice guidelines of acromegaly
Frara et al. The modern criteria for medical management of acromegaly
Cordido et al. Practical guidelines for diagnosis and treatment of acromegaly
Klubo-Gwiezdzinska et al. Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer
Borson-Chazot et al. Guidelines for the management of differentiated thyroid carcinomas of vesicular origin: recommandations pour la prise en charge des cancers thyroïdiens différenciés de souche vésiculaire
Chiam et al. Oncogenic osteomalacia—hypophosphataemic spectrum from “benignancy” to “malignancy”
Driedger et al. Two cases of thyroid carcinoma that were not stimulated by recombinant human thyrotropin
Wydra et al. Skeletal complications in acromegaly
Al‐Hadlaq et al. Acromegaly: Overview and associated temporomandibular joint disorders
Maione et al. Acromegaly
Dhaneshwar et al. Growth hormone excess: Implications and management
Cardoso et al. Diagnosis and management of acromegaly: a consensus statement of the pituitary study group of the portuguese society of endocrinology, diabetes and metabolism
Zhang et al. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly
Cook et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of Acromegaly
Berg et al. Development of severe thyroid-associated ophthalmopathy in a patient with disseminated thyroid cancer treated with recombinant human thyrotropin/radioiodine and retinoic acid
Wu et al. Association of radiotherapy with thoracic vertebral fractures in esophageal squamous cell carcinoma: a retrospective cohort study
Emodi et al. Maxillary tumour-induced osteomalacia
Chew et al. Clinical endocrinology and diabetes: an illustrated colour text
Oduwegwu et al. Male hypogonadism and osteoporosis: a systematic review